NZ537277A - Recombinant production of mixtures of antibodies - Google Patents
Recombinant production of mixtures of antibodiesInfo
- Publication number
- NZ537277A NZ537277A NZ537277A NZ53727703A NZ537277A NZ 537277 A NZ537277 A NZ 537277A NZ 537277 A NZ537277 A NZ 537277A NZ 53727703 A NZ53727703 A NZ 53727703A NZ 537277 A NZ537277 A NZ 537277A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibodies
- cells
- mixture
- cell
- light chain
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 282
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 82
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 109
- 239000000427 antigen Substances 0.000 claims abstract description 82
- 108091007433 antigens Proteins 0.000 claims abstract description 81
- 102000036639 antigens Human genes 0.000 claims abstract description 81
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 36
- 238000000034 method Methods 0.000 claims description 169
- 230000014509 gene expression Effects 0.000 claims description 71
- 108090000623 proteins and genes Proteins 0.000 claims description 59
- 102000004169 proteins and genes Human genes 0.000 claims description 47
- 108020004707 nucleic acids Proteins 0.000 claims description 37
- 102000039446 nucleic acids Human genes 0.000 claims description 37
- 238000004113 cell culture Methods 0.000 claims description 13
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 9
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 9
- 230000003321 amplification Effects 0.000 claims description 7
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 7
- 239000000539 dimer Substances 0.000 claims description 4
- 210000001525 retina Anatomy 0.000 claims description 4
- 230000027455 binding Effects 0.000 abstract description 95
- 238000009739 binding Methods 0.000 abstract description 92
- 210000004027 cell Anatomy 0.000 description 414
- 238000001155 isoelectric focusing Methods 0.000 description 45
- 235000018102 proteins Nutrition 0.000 description 42
- 238000003556 assay Methods 0.000 description 39
- 239000006228 supernatant Substances 0.000 description 37
- 230000009261 transgenic effect Effects 0.000 description 37
- 238000002965 ELISA Methods 0.000 description 34
- 108090000765 processed proteins & peptides Proteins 0.000 description 33
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 30
- 241001465754 Metazoa Species 0.000 description 29
- 239000002609 medium Substances 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 24
- 238000011282 treatment Methods 0.000 description 24
- 101000961414 Homo sapiens Membrane cofactor protein Proteins 0.000 description 22
- 238000002823 phage display Methods 0.000 description 22
- 238000001890 transfection Methods 0.000 description 22
- 241000196324 Embryophyta Species 0.000 description 21
- 239000013604 expression vector Substances 0.000 description 21
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 101900083372 Rabies virus Glycoprotein Proteins 0.000 description 20
- 241000700605 Viruses Species 0.000 description 20
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Natural products O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 19
- 238000011534 incubation Methods 0.000 description 19
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 19
- 102100039373 Membrane cofactor protein Human genes 0.000 description 18
- 238000001042 affinity chromatography Methods 0.000 description 18
- 238000012258 culturing Methods 0.000 description 18
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 description 17
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 17
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 description 17
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 17
- 108060003951 Immunoglobulin Proteins 0.000 description 17
- 102000018358 immunoglobulin Human genes 0.000 description 17
- 239000002953 phosphate buffered saline Substances 0.000 description 17
- 102000006354 HLA-DR Antigens Human genes 0.000 description 16
- 108010058597 HLA-DR Antigens Proteins 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 239000000047 product Substances 0.000 description 16
- 238000012216 screening Methods 0.000 description 16
- 210000001519 tissue Anatomy 0.000 description 16
- 241000894006 Bacteria Species 0.000 description 15
- 239000013598 vector Substances 0.000 description 15
- 210000003719 b-lymphocyte Anatomy 0.000 description 14
- 239000012737 fresh medium Substances 0.000 description 14
- 238000002825 functional assay Methods 0.000 description 14
- 238000010561 standard procedure Methods 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 150000002500 ions Chemical class 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 238000001712 DNA sequencing Methods 0.000 description 12
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 12
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 235000021186 dishes Nutrition 0.000 description 12
- 102000037865 fusion proteins Human genes 0.000 description 12
- 108020001507 fusion proteins Proteins 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 235000013336 milk Nutrition 0.000 description 11
- 239000008267 milk Substances 0.000 description 11
- 210000004080 milk Anatomy 0.000 description 11
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 102000012804 EPCAM Human genes 0.000 description 10
- 101150084967 EPCAM gene Proteins 0.000 description 10
- 108010029485 Protein Isoforms Proteins 0.000 description 10
- 102000001708 Protein Isoforms Human genes 0.000 description 10
- 101150057140 TACSTD1 gene Proteins 0.000 description 10
- 108700019146 Transgenes Proteins 0.000 description 10
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 230000001143 conditioned effect Effects 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- 108090000672 Annexin A5 Proteins 0.000 description 9
- 102000004121 Annexin A5 Human genes 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 230000002068 genetic effect Effects 0.000 description 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 8
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 8
- 241001529936 Murinae Species 0.000 description 8
- 238000002105 Southern blotting Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 8
- 238000013459 approach Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 238000010367 cloning Methods 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 229940072221 immunoglobulins Drugs 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 239000013613 expression plasmid Substances 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 239000000833 heterodimer Substances 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 101000840258 Homo sapiens Immunoglobulin J chain Proteins 0.000 description 6
- 102100029571 Immunoglobulin J chain Human genes 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 206010037742 Rabies Diseases 0.000 description 6
- 239000004098 Tetracycline Substances 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 6
- 229960000723 ampicillin Drugs 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000012636 effector Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 238000000684 flow cytometry Methods 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 238000010899 nucleation Methods 0.000 description 6
- 239000008188 pellet Substances 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 229960002180 tetracycline Drugs 0.000 description 6
- 229930101283 tetracycline Natural products 0.000 description 6
- 235000019364 tetracycline Nutrition 0.000 description 6
- 150000003522 tetracyclines Chemical class 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 241000701022 Cytomegalovirus Species 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 5
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000003466 anti-cipated effect Effects 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 241000233866 Fungi Species 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 108010004729 Phycoerythrin Proteins 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 241000276498 Pollachius virens Species 0.000 description 4
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229960001031 glucose Drugs 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 210000004408 hybridoma Anatomy 0.000 description 4
- 239000012678 infectious agent Substances 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 210000005075 mammary gland Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 238000012510 peptide mapping method Methods 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000011830 transgenic mouse model Methods 0.000 description 4
- VHJLVAABSRFDPM-UHFFFAOYSA-N 1,4-dithiothreitol Chemical compound SCC(O)C(O)CS VHJLVAABSRFDPM-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 244000061176 Nicotiana tabacum Species 0.000 description 3
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 208000035415 Reinfection Diseases 0.000 description 3
- 108010052160 Site-specific recombinase Proteins 0.000 description 3
- 240000008042 Zea mays Species 0.000 description 3
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 3
- 238000004115 adherent culture Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000012620 biological material Substances 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- 238000005277 cation exchange chromatography Methods 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000022534 cell killing Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012761 co-transfection Methods 0.000 description 3
- 238000001360 collision-induced dissociation Methods 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000016784 immunoglobulin production Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 238000002702 ribosome display Methods 0.000 description 3
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 238000004114 suspension culture Methods 0.000 description 3
- 238000013519 translation Methods 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 101710087237 Whey acidic protein Proteins 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000009824 affinity maturation Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003636 conditioned culture medium Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000001085 cytostatic effect Effects 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 229960005156 digoxin Drugs 0.000 description 2
- 108020001096 dihydrofolate reductase Proteins 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 108010074605 gamma-Globulins Proteins 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 102000044446 human CD46 Human genes 0.000 description 2
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
- 239000012642 immune effector Substances 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 229930027917 kanamycin Natural products 0.000 description 2
- 229960000318 kanamycin Drugs 0.000 description 2
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 2
- 229930182823 kanamycin A Natural products 0.000 description 2
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 238000002824 mRNA display Methods 0.000 description 2
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 230000017066 negative regulation of growth Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002818 protein evolution Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 2
- 238000004885 tandem mass spectrometry Methods 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 241000710929 Alphavirus Species 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 101100519158 Arabidopsis thaliana PCR2 gene Proteins 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108091008875 B cell receptors Proteins 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
- 102100022002 CD59 glycoprotein Human genes 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 244000228088 Cola acuminata Species 0.000 description 1
- 235000010205 Cola acuminata Nutrition 0.000 description 1
- 235000015438 Cola nitida Nutrition 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
- 108050004280 Epsilon toxin Proteins 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 241000219146 Gossypium Species 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 206010061192 Haemorrhagic fever Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000897400 Homo sapiens CD59 glycoprotein Proteins 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 1
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000342334 Human metapneumovirus Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 241000712890 Junin mammarenavirus Species 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 241000711828 Lyssavirus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 101710202365 Napin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 101800005149 Peptide B Proteins 0.000 description 1
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 1
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 1
- 240000007377 Petunia x hybrida Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108700001094 Plant Genes Proteins 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000029797 Prion Human genes 0.000 description 1
- 108091000054 Prion Proteins 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 108010034949 Thyroglobulin Proteins 0.000 description 1
- 102000009843 Thyroglobulin Human genes 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 230000010530 Virus Neutralization Effects 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000235013 Yarrowia Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 229920002494 Zein Polymers 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000002942 anti-growth Effects 0.000 description 1
- 230000001494 anti-thymocyte effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229960004669 basiliximab Drugs 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- BQRGNLJZBFXNCZ-UHFFFAOYSA-N calcein am Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=C(OC(C)=O)C=C1OC1=C2C=C(CN(CC(=O)OCOC(C)=O)CC(=O)OCOC(=O)C)C(OC(C)=O)=C1 BQRGNLJZBFXNCZ-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003034 chemosensitisation Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229940108471 crofab Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- -1 etc Proteins 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000011990 functional testing Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000521 hyperimmunizing effect Effects 0.000 description 1
- 238000011575 immunodeficient mouse model Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 238000010872 live dead assay kit Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 201000011475 meningoencephalitis Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000001823 molecular biology technique Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 229960000951 mycophenolic acid Drugs 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000287 oocyte Anatomy 0.000 description 1
- 230000014207 opsonization Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 210000002706 plastid Anatomy 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000011809 primate model Methods 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000004850 protein–protein interaction Effects 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000019254 respiratory burst Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000003998 snake venom Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229960002175 thyroglobulin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 244000045561 useful plants Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 231100000747 viability assay Toxicity 0.000 description 1
- 238000003026 viability measurement method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
- 239000005019 zein Substances 0.000 description 1
- 229940093612 zein Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Transplantation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39706602P | 2002-07-18 | 2002-07-18 | |
| EP02077953 | 2002-07-18 | ||
| EPPCT/EP03/50201 | 2003-05-27 | ||
| PCT/EP2003/007690 WO2004009618A2 (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ537277A true NZ537277A (en) | 2008-04-30 |
Family
ID=43768900
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ537277A NZ537277A (en) | 2002-07-18 | 2003-07-15 | Recombinant production of mixtures of antibodies |
Country Status (14)
| Country | Link |
|---|---|
| US (9) | US7262028B2 (enExample) |
| EP (2) | EP2314629B2 (enExample) |
| JP (4) | JP4836451B2 (enExample) |
| CN (3) | CN100480260C (enExample) |
| AT (1) | ATE514717T1 (enExample) |
| AU (2) | AU2003250074B2 (enExample) |
| CA (3) | CA2965865C (enExample) |
| CY (1) | CY1111886T1 (enExample) |
| DK (2) | DK1523496T3 (enExample) |
| ES (2) | ES2368733T3 (enExample) |
| NZ (1) | NZ537277A (enExample) |
| PT (2) | PT2314629E (enExample) |
| SI (1) | SI1523496T1 (enExample) |
| WO (1) | WO2004009618A2 (enExample) |
Families Citing this family (303)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445322B2 (en) | 1995-06-15 | 2012-06-06 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US6783980B2 (en) * | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| US20050164386A1 (en) * | 1999-04-15 | 2005-07-28 | Uytdehaag Alphonsus G. | Overexpression of enzymes involved in post-translational protein modifications in human cells |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| US8236561B2 (en) * | 1999-04-15 | 2012-08-07 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| US7297680B2 (en) * | 1999-04-15 | 2007-11-20 | Crucell Holland B.V. | Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| US7521220B2 (en) * | 1999-11-26 | 2009-04-21 | Crucell Holland B.V. | Production of vaccines |
| US7658924B2 (en) * | 2001-10-11 | 2010-02-09 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7521053B2 (en) * | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| ATE542904T1 (de) * | 2001-10-29 | 2012-02-15 | Crucell Holland Bv | Verfahren und mittel zur herstellung von proteinen mit vorbestimmten posttranslationalen modifikationen |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| SI1523496T1 (sl) * | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| ES2424269T3 (es) * | 2002-11-01 | 2013-09-30 | Iris International, Inc. | Inmuno-PCR sándwich por desplazamiento |
| GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| WO2004065611A1 (ja) * | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体の軽鎖スクリーニング方法 |
| DK1626992T3 (da) * | 2003-05-23 | 2010-09-20 | Crucell Holland Bv | Produktion af rekombinant IgM i PER.C6-celler |
| EP2395017A3 (en) * | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP1508576A1 (en) * | 2003-08-20 | 2005-02-23 | Crucell Holland B.V. | Efficient production of IgA in recombinant mammalian cells |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| AU2011218688B2 (en) * | 2004-05-27 | 2013-01-10 | Crucell Holland B.V. | Binding molecules capable of neutralizing rabies virus and uses thereof |
| HRP20110320T1 (hr) | 2004-05-27 | 2011-05-31 | Crucell Holland B.V. | Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba |
| US7973134B2 (en) | 2004-07-07 | 2011-07-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways |
| RU2426795C2 (ru) | 2004-07-20 | 2011-08-20 | Симфоген А/С | Способ структурной характеристики рекомбинантного поликлонального белка или поликлональной клеточной линии |
| BRPI0513706A (pt) | 2004-07-20 | 2008-05-13 | Symphogen As | anticorpo policlonal recombinante anti-rhesus d e métodos de produção |
| US7935790B2 (en) | 2004-10-04 | 2011-05-03 | Cell Singaling Technology, Inc. | Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways |
| PT1815028E (pt) * | 2004-11-03 | 2012-01-24 | Iris Molecular Diagnostics Inc | Microbolhas para separação por afinidade |
| JP5188808B2 (ja) * | 2004-11-03 | 2013-04-24 | アイリス モレキュラー ダイアグノスティクス， インコーポレイテッド | 同種の分析物検出 |
| US7807789B2 (en) | 2004-12-21 | 2010-10-05 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in EGFR-signaling pathways |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| EP1876236B9 (en) * | 2005-04-08 | 2015-02-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody substituting for function of blood coagulation factor viii |
| PL1874821T3 (pl) | 2005-04-26 | 2013-09-30 | Trion Pharma Gmbh | Kombinacja przeciwciał i glikokortykoidów do leczenia raka |
| EP1934867A2 (en) | 2005-08-31 | 2008-06-25 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| US20070111237A1 (en) * | 2005-09-14 | 2007-05-17 | Maurizio Zanetti | Process for identifying antigenized antibodies using ribosome cell free expression system |
| AU2012201010B2 (en) * | 2005-10-21 | 2015-01-22 | Genzyme Corporation | Antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
| NZ568433A (en) * | 2005-10-21 | 2012-07-27 | Gtc Biotherapeutics Inc | Milk-derived antibodies with enhanced antibody-dependent cellular cytoxicity activity, methods of their production and use |
| DE102005054628A1 (de) * | 2005-11-16 | 2007-05-24 | Cevec Pharmaceuticals Gmbh | Verfahren zur Herstellung von permanenten humanen Zelllinien |
| JP2009518320A (ja) | 2005-12-05 | 2009-05-07 | シュムフォウエン アクティーゼルスカブ | 抗オルトポックスウイルス組換えポリクローナル抗体 |
| US20120208824A1 (en) | 2006-01-20 | 2012-08-16 | Cell Signaling Technology, Inc. | ROS Kinase in Lung Cancer |
| BRPI0707958B8 (pt) * | 2006-02-17 | 2021-07-27 | Sekiyama Atsuo | composição e kit para testar condições mentais por uma análise de regressão logística e método de medição de condições mentais |
| DK2359834T5 (en) | 2006-03-15 | 2017-02-06 | Alexion Pharma Inc | Treatment of paroxysmal nocturnal hemoglobinuria patients with a complement inhibitor |
| EP2009101B1 (en) | 2006-03-31 | 2017-10-25 | Chugai Seiyaku Kabushiki Kaisha | Antibody modification method for purifying bispecific antibody |
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| US7939636B2 (en) | 2006-08-11 | 2011-05-10 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in c-Src signaling pathways |
| WO2008027986A2 (en) | 2006-09-01 | 2008-03-06 | Therapeutic Human Polyclonals, Inc. | Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals |
| EP2380907B1 (en) | 2006-09-05 | 2016-11-30 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| WO2008068246A1 (en) | 2006-12-05 | 2008-06-12 | Crucell Holland B.V. | Liquid anti-rabies antibody formulations |
| PL2132229T3 (pl) | 2007-03-01 | 2016-12-30 | Kompozycje rekombinowanych przeciwciał anty-receptor czynnika wzrostu naskórka | |
| US20090081659A1 (en) | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1975184A3 (en) | 2007-03-26 | 2008-11-26 | Cell Signaling Technology, Inc. | Serine or threonine phosphorylation sites |
| NL1033696C2 (nl) * | 2007-04-16 | 2008-10-20 | Friesland Brands Bv | Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan. |
| US7977462B2 (en) | 2007-04-19 | 2011-07-12 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| EP1983003A3 (en) | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| EP2145902A3 (en) | 2007-04-19 | 2010-09-29 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| US20090053831A1 (en) | 2007-05-01 | 2009-02-26 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
| NZ581316A (en) * | 2007-05-25 | 2012-02-24 | Symphogen As | Method for manufacturing a recombinant polyclonal protein |
| WO2009002380A2 (en) * | 2007-06-26 | 2008-12-31 | The Trustees Of The University Of Pennsylvania | Isolation of anti-desmoglein 1 antibodies by phage display of pemphigus foliaceus autoantibodies |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| JP5769968B2 (ja) | 2007-10-18 | 2015-08-26 | セル・シグナリング・テクノロジー・インコーポレイテツド | ヒト非小細胞肺癌における転座および変異ｒｏｓキナーゼ |
| US20090203043A1 (en) | 2007-11-21 | 2009-08-13 | Peter Hornbeck | Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| US20090246781A1 (en) * | 2008-02-21 | 2009-10-01 | Robert Klem | Method for early determination of recurrence after therapy for prostate cancer |
| EP2098536A1 (en) | 2008-03-05 | 2009-09-09 | 4-Antibody AG | Isolation and identification of antigen- or ligand-specific binding proteins |
| CA2718975A1 (en) | 2008-04-10 | 2009-10-15 | Cell Signaling Technology, Inc. | Compositions and methods for detecting egfr mutations in cancer |
| BRPI0910454A2 (pt) * | 2008-04-23 | 2018-03-27 | Symphogen As | processo para produção de uma proteína policlonal |
| CN102076355B (zh) | 2008-04-29 | 2014-05-07 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| SG191639A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| RU2559524C2 (ru) | 2008-06-27 | 2015-08-10 | Мерюс Б.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
| US8148088B2 (en) | 2008-07-18 | 2012-04-03 | Abgent | Regulation of autophagy pathway phosphorylation and uses thereof |
| EP2331577B1 (en) | 2008-08-29 | 2017-06-07 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
| EP2159291A1 (en) | 2008-09-01 | 2010-03-03 | Agendia B.V. | Means and method for determining tumor cell percentage in a sample |
| CN102365296A (zh) * | 2009-01-26 | 2012-02-29 | 根马布股份公司 | 用于生成抗体混合物的方法 |
| DK2393927T3 (en) | 2009-02-09 | 2015-03-30 | Morphosys Ag | Preparation of oligoclonal mixtures of antibodies in the individual cells |
| AU2010213578B2 (en) | 2009-02-12 | 2015-01-29 | Cell Signaling Technology, Inc. | Mutant ROS expression in human cancer |
| PE20160653A1 (es) | 2009-03-05 | 2016-07-24 | Abbvie Inc | Proteinas de union a il-17 |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| EP3028565B1 (en) | 2009-07-08 | 2017-09-27 | Kymab Limited | Animal models and therapeutic molecules |
| PE20121647A1 (es) | 2009-08-29 | 2012-12-31 | Abbvie Inc | Proteinas terapeuticas de union a dll4 |
| JP6184695B2 (ja) * | 2009-12-04 | 2017-08-23 | ジェネンテック， インコーポレイテッド | 多重特異性抗体、抗体アナログ、組成物、及び方法 |
| SMT201900372T1 (it) * | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20120021409A1 (en) * | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| DK2560683T4 (da) | 2010-04-23 | 2022-08-29 | Hoffmann La Roche | Fremstilling af heteromultimeriske proteiner |
| EP2571532B1 (en) | 2010-05-14 | 2017-05-03 | Abbvie Inc. | Il-1 binding proteins |
| UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| RU2612903C2 (ru) | 2010-08-02 | 2017-03-13 | Ридженерон Фармасьютикалз, Инк. | Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены |
| TW201206473A (en) | 2010-08-03 | 2012-02-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2012019132A2 (en) | 2010-08-06 | 2012-02-09 | Cell Signaling Technology, Inc. | Anaplastic lymphoma kinase in kidney cancer |
| EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| CN103260639A (zh) | 2010-08-26 | 2013-08-21 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
| CN103476429B (zh) | 2010-09-03 | 2016-08-24 | 施特姆森特克斯股份有限公司 | 新型调节剂及使用方法 |
| TR201802772T4 (tr) | 2010-11-17 | 2018-03-21 | Chugai Pharmaceutical Co Ltd | Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül. |
| MY163368A (en) | 2010-12-21 | 2017-09-15 | Abbvie Inc | Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use |
| WO2012094321A1 (en) | 2011-01-03 | 2012-07-12 | Avm Biotechnology, Llc | Personalized production of biologics and method for reprogramming somatic cells |
| DK2813573T1 (da) | 2011-02-25 | 2015-01-12 | Regeneron Pharma | ADAM6 mus |
| WO2012122512A1 (en) | 2011-03-10 | 2012-09-13 | Hco Antibody, Inc. | Recombinant production of mixtures of single chain antibodies |
| US9244074B2 (en) | 2011-06-07 | 2016-01-26 | University Of Hawaii | Biomarker of asbestos exposure and mesothelioma |
| WO2012170742A2 (en) | 2011-06-07 | 2012-12-13 | University Of Hawaii | Treatment and prevention of cancer with hmgb1 antagonists |
| UA117901C2 (uk) | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
| HUE068728T2 (hu) * | 2011-08-05 | 2025-01-28 | Regeneron Pharma | Humanizált univerzális könnyûláncú egerek |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| HRP20190044T1 (hr) | 2011-09-23 | 2019-02-22 | Oncomed Pharmaceuticals, Inc. | Agensi koji vežu vegf/dll4 i njihove uporabe |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| ES2971444T3 (es) | 2011-10-11 | 2024-06-05 | F Hoffmann Lar Roche Ag | Ensamblaje mejorado de anticuerpos biespecíficos |
| PL3216871T3 (pl) | 2011-10-17 | 2022-03-21 | Regeneron Pharmaceuticals, Inc. | Ograniczony łańcuch ciężki immonoglobuliny pochodzącej od myszy |
| JP2014533659A (ja) | 2011-10-24 | 2014-12-15 | アッヴィ・インコーポレイテッド | スクレロスチンに対するイムノバインダー |
| UY34410A (es) | 2011-10-24 | 2013-05-31 | Abbvie Inc | Inmunoligantes biespecificos dirigidos contra tnf |
| US9220774B2 (en) | 2011-11-01 | 2015-12-29 | Bionomics Inc. | Methods of treating cancer by administering anti-GPR49 antibodies |
| WO2013067055A1 (en) | 2011-11-01 | 2013-05-10 | Bionomics, Inc. | Methods of blocking cancer stem cell growth |
| AU2012332593B2 (en) | 2011-11-01 | 2016-11-17 | Bionomics, Inc. | Anti-GPR49 antibodies |
| AU2012332587B2 (en) | 2011-11-01 | 2017-02-23 | Bionomics, Inc. | Antibodies and methods of treating cancer |
| MX378871B (es) | 2011-12-20 | 2025-03-10 | Regeneron Pharma | Ratones con cadena ligera humanizada. |
| US8962315B2 (en) | 2011-12-22 | 2015-02-24 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen |
| US9175072B2 (en) | 2011-12-22 | 2015-11-03 | Elwha Llc | Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen |
| US10233424B2 (en) | 2011-12-22 | 2019-03-19 | Elwha Llc | Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin |
| US10745468B2 (en) | 2011-12-22 | 2020-08-18 | Kota Biotherapeutics, Llc | Compositions and methods for modified B cells expressing reassigned biological agents |
| WO2013102042A2 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual specific binding proteins directed against il-13 and/or il-17 |
| US20130171059A1 (en) | 2011-12-30 | 2013-07-04 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| US9550830B2 (en) | 2012-02-15 | 2017-01-24 | Novo Nordisk A/S | Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1) |
| AU2013204140B2 (en) * | 2012-03-06 | 2016-01-28 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| EP3348140B1 (en) | 2012-03-16 | 2020-12-30 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| CA2865644A1 (en) | 2012-03-16 | 2013-09-19 | Regeneron Pharmaceuticals, Inc. | Mice that produce antigen-binding proteins with ph-dependent binding characteristics |
| KR102213535B1 (ko) | 2012-03-16 | 2021-02-08 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| DK2838998T3 (en) | 2012-04-18 | 2018-01-15 | Cell Signaling Technology Inc | EGFR AND ROS1 IN CANCER |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| AU2013259276B2 (en) * | 2012-05-10 | 2018-03-22 | Bioatla Llc | Multi-specific monoclonal antibodies |
| EP2858487B1 (en) | 2012-06-12 | 2019-10-23 | Regeneron Pharmaceuticals, Inc. | Humanized non-human animals with restricted immunoglobulin heavy chain loci |
| CN104736174B (zh) | 2012-07-06 | 2019-06-14 | 根马布私人有限公司 | 具有三重突变的二聚体蛋白质 |
| EP3632462A1 (en) | 2012-07-06 | 2020-04-08 | Genmab B.V. | Dimeric protein with triple mutations |
| WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
| CN102851338A (zh) | 2012-07-25 | 2013-01-02 | 苏州康宁杰瑞生物科技有限公司 | 利用电荷排斥作用制备同二聚体蛋白混合物的方法 |
| ES2456823B1 (es) * | 2012-09-21 | 2015-01-27 | Consejo Superior De Investigaciones Científicas (Csic) | Método de producción de repertorios complejos de moléculas recombinantes |
| US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
| HK1212359A1 (en) | 2012-11-01 | 2016-06-10 | Abbvie Inc. | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| CN110669136A (zh) * | 2012-11-05 | 2020-01-10 | 全药工业株式会社 | 抗体或抗体组合物的制备方法 |
| CA2890455A1 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
| US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| WO2014106001A2 (en) | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
| KR20200024345A (ko) | 2013-01-10 | 2020-03-06 | 젠맵 비. 브이 | 인간 IgG1 Fc 영역 변이체 및 그의 용도 |
| EP2946016A4 (en) * | 2013-01-15 | 2016-11-23 | Univ California | ADENOVIRES AND THEIR USE |
| RS57582B1 (sr) | 2013-02-20 | 2018-11-30 | Regeneron Pharma | Nehumane životinje sa modifikovanim sekvencama imunoglobulinskog teškog lanca |
| RU2015143108A (ru) * | 2013-03-13 | 2017-04-20 | Регенерон Фарматютикалз, Инк. | Мышь с общей легкой цепью |
| JP2016522793A (ja) | 2013-03-15 | 2016-08-04 | アッヴィ・インコーポレイテッド | ＩＬ−１βおよび／またはＩＬ−１７に対して指向された二重特異的結合タンパク質 |
| WO2014144299A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST TNFα |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| ME03675B (me) | 2013-07-05 | 2020-10-20 | Genmab As | Humanizovana ili himerna anтi-cd3 antiтela |
| US10208125B2 (en) | 2013-07-15 | 2019-02-19 | University of Pittsburgh—of the Commonwealth System of Higher Education | Anti-mucin 1 binding agents and uses thereof |
| ES2881306T3 (es) | 2013-09-27 | 2021-11-29 | Chugai Pharmaceutical Co Ltd | Método para la producción de heteromultímeros de polipéptidos |
| WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
| WO2015051379A2 (en) | 2013-10-06 | 2015-04-09 | Abbvie Inc. | Dual specific binding proteins directed against immune cell receptors and autoantigens |
| US20150203592A1 (en) | 2013-12-02 | 2015-07-23 | Abbvie Inc. | Compositions and methods for treating osteoarthritis |
| WO2015120474A1 (en) * | 2014-02-10 | 2015-08-13 | Igm Biosciences, Inc. | Iga multi-specific binding molecules |
| SG11201607109QA (en) | 2014-02-28 | 2016-09-29 | Merus Nv | Antibodies that bind egfr and erbb3 |
| SI3110849T1 (sl) | 2014-02-28 | 2021-01-29 | Merus N.V. | Protitelo, ki veže ERBB-2 in ERBB-3 |
| RU2016141307A (ru) | 2014-03-21 | 2018-04-24 | Регенерон Фармасьютикалз, Инк. | Отличные от человека животные, которые вырабатывают однодоменные связывающие белки |
| WO2015143406A2 (en) | 2014-03-21 | 2015-09-24 | Regeneron Pharmaceuticals, Inc. | Vl antigen binding proteins exhibiting distinct binding characteristics |
| US20170022291A1 (en) | 2014-04-01 | 2017-01-26 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
| CA2944647C (en) | 2014-04-03 | 2025-07-08 | Igm Biosciences Inc | MODIFIED J STRING |
| AU2015240599B2 (en) | 2014-04-04 | 2020-11-19 | Bionomics, Inc. | Humanized antibodies that bind LGR5 |
| ES2955736T3 (es) | 2014-05-06 | 2023-12-05 | Hoffmann La Roche | Producción de proteínas heteromultiméricas usando células de mamífero |
| SG11201609207SA (en) | 2014-05-13 | 2016-12-29 | Univ Pennsylvania | Compositions comprising aav expressing dual antibody constructs and uses thereof |
| ES2774428T3 (es) | 2014-07-11 | 2020-07-21 | Genmab As | Anticuerpos que se unen a AXL |
| AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| MA40764A (fr) | 2014-09-26 | 2017-08-01 | Chugai Pharmaceutical Co Ltd | Agent thérapeutique induisant une cytotoxicité |
| TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體 |
| TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定ｆｖｉｉｉ的反應性之方法 |
| RU2715905C2 (ru) | 2014-10-01 | 2020-03-04 | МЕДИММЬЮН, ЭлЭлСи | Способ конъюгации полипептида |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| CN110658340B (zh) * | 2015-01-08 | 2023-10-31 | 苏州康宁杰瑞生物科技有限公司 | 具有共同轻链的双特异性抗体或抗体混合物 |
| US10689449B2 (en) | 2015-01-20 | 2020-06-23 | Igm Biosciences, Inc. | Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereof |
| IL297997A (en) | 2015-03-04 | 2023-01-01 | Igm Biosciences Inc | Cd20 binding molecules and uses thereof |
| US11111314B2 (en) | 2015-03-19 | 2021-09-07 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3345928B1 (en) | 2015-07-10 | 2020-06-24 | Merus N.V. | Human cd3 binding antibody |
| LT3319993T (lt) | 2015-07-10 | 2020-05-11 | Genmab A/S | Axl specifiniai antikūno-vaistokonjugatai, skirti vėžiui gydyti |
| IL256562B2 (en) | 2015-07-15 | 2024-07-01 | Genmab As | Human CD3 antibodies or chimeras |
| CA2995724A1 (en) * | 2015-08-27 | 2017-03-02 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having a common light chain |
| HUE069387T2 (hu) | 2015-09-30 | 2025-03-28 | Igm Biosciences Inc | Módosított J-lánccal rendelkezõ kötõmolekulák |
| US11639389B2 (en) | 2015-09-30 | 2023-05-02 | Igm Biosciences, Inc. | Binding molecules with modified J-chain |
| BR112018008068A2 (en) | 2015-10-23 | 2018-11-13 | Merus N.V. | binding molecules that inhibit cancer growth |
| JP6954842B2 (ja) | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| JP7219005B2 (ja) | 2015-12-28 | 2023-02-07 | 中外製薬株式会社 | Ｆｃ領域含有ポリペプチドの精製を効率化するための方法 |
| JP6991978B2 (ja) | 2016-01-27 | 2022-02-03 | メディミューン，エルエルシー | 定められるグリコシル化パターンを有する抗体を調製するための方法 |
| US11291721B2 (en) | 2016-03-21 | 2022-04-05 | Marengo Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN108697799A (zh) | 2016-03-22 | 2018-10-23 | 生态学有限公司 | 抗lgr5单克隆抗体的施用 |
| JP7320943B2 (ja) | 2016-04-28 | 2023-08-04 | 中外製薬株式会社 | 抗体含有製剤 |
| CA3025162A1 (en) | 2016-05-26 | 2017-11-30 | Qilu Puget Sound Biotherapeutics Corporation | Mixtures of antibodies |
| UA128304C2 (uk) | 2016-07-14 | 2024-06-05 | Ґенмаб А/С | Мультиспецифічне антитіло до cd40 і cd137 |
| BR112019003989A2 (pt) | 2016-09-06 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | métodos de utilização de um anticorpo biespecífico que reconhece o fator de coagulação ix e/ou o fator de coagulação ix ativado e o fator de coagulação x e/ou o fator de coagulação x ativado |
| CN117510643A (zh) | 2016-09-23 | 2024-02-06 | 美勒斯公司 | 调节细胞表达的生物活性的结合分子 |
| EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| US11447789B2 (en) | 2016-12-01 | 2022-09-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence | Production in plants of ricin antibodies that bind to ricin B chain |
| JP7123063B2 (ja) * | 2017-02-02 | 2022-08-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗体ドメインの好ましい対形成 |
| KR20250140128A (ko) | 2017-02-10 | 2025-09-24 | 젠맵 비. 브이 | 폴리펩티드 변이체 및 그의 용도 |
| US20200291089A1 (en) | 2017-02-16 | 2020-09-17 | Elstar Therapeutics, Inc. | Multifunctional molecules comprising a trimeric ligand and uses thereof |
| CN116836285A (zh) | 2017-03-09 | 2023-10-03 | 健玛保 | 针对pd-l1的抗体 |
| CA3058343A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb-3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene |
| WO2018182421A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |
| EP3601354A1 (en) | 2017-03-31 | 2020-02-05 | Genmab Holding B.V. | Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof |
| US12195551B2 (en) | 2017-05-17 | 2025-01-14 | Merus N.V. | Combination of an ErbB-2/ErbB-3 bispecific antibody with endocrine therapy for breast cancer |
| AR111963A1 (es) | 2017-05-26 | 2019-09-04 | Univ California | Método y moléculas |
| EP3630836A1 (en) | 2017-05-31 | 2020-04-08 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof |
| UY37758A (es) | 2017-06-12 | 2019-01-31 | Novartis Ag | Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos |
| IL271832B2 (en) | 2017-07-06 | 2025-07-01 | Merus Nv | Bispecific anti pd1-anti tim3 antibodies and uses thereof |
| WO2019009728A1 (en) | 2017-07-06 | 2019-01-10 | Merus N.V. | ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL |
| CN119119284A (zh) | 2017-07-06 | 2024-12-13 | 美勒斯公司 | 调节由细胞表达的生物活性的结合分子 |
| GB201710984D0 (en) * | 2017-07-07 | 2017-08-23 | Kymab Ltd | Cells, vertebrates, populations & methods |
| JP7290013B2 (ja) | 2017-08-04 | 2023-06-13 | ジェンマブ エー／エス | Ｐｄ－ｌ１およびｃｄ１３７に結合する結合物質ならびにその使用 |
| HUE071182T2 (hu) | 2017-08-09 | 2025-08-28 | Merus Nv | EGFR és CMET kötõ antitestek |
| UA128389C2 (uk) | 2017-09-29 | 2024-07-03 | Чугаі Сейяку Кабусікі Кайся | Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт |
| AU2018361430B2 (en) | 2017-11-01 | 2025-08-14 | Chugai Seiyaku Kabushiki Kaisha | Antibody variant and isoform with lowered biological activity |
| US11746150B2 (en) * | 2017-12-19 | 2023-09-05 | Surrozen Operating, Inc. | Anti-LRP5/6 antibodies and methods of use |
| US11773171B2 (en) | 2017-12-19 | 2023-10-03 | Surrozen Operating, Inc. | WNT surrogate molecules and uses thereof |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| JP2021510740A (ja) | 2018-01-24 | 2021-04-30 | ゲンマブ ビー．ブイ． | ポリペプチド変種およびそれらの用途 |
| TWI804572B (zh) | 2018-02-09 | 2023-06-11 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| EP3765493A2 (en) | 2018-03-12 | 2021-01-20 | Genmab A/S | Antibodies |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| US20210009711A1 (en) | 2018-03-14 | 2021-01-14 | Elstar Therapeutics, Inc. | Multifunctional molecules and uses thereof |
| WO2019182910A1 (en) * | 2018-03-19 | 2019-09-26 | Elwha Llc | Compositions and methods for modified b cells expressing reassigned biological agents |
| MX2020010267A (es) | 2018-03-30 | 2020-11-06 | Merus Nv | Anticuerpo multivalente. |
| MX2020011552A (es) | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| MA52945A (fr) | 2018-06-22 | 2021-04-28 | Genmab As | Procédé de production d'un mélange contrôlé d'au moins deux anticorps différents |
| EP3810194A1 (en) | 2018-06-22 | 2021-04-28 | Genmab Holding B.V. | Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof |
| AU2019297451A1 (en) | 2018-07-03 | 2021-01-28 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
| US20240254252A1 (en) | 2018-07-13 | 2024-08-01 | Genmab A/S | Trogocytosis-mediated therapy using cd38 antibodies |
| CA3106146A1 (en) | 2018-07-13 | 2020-01-16 | Genmab A/S | Variants of cd38 antibody and uses thereof |
| MA53812A (fr) | 2018-10-04 | 2021-08-11 | Genmab Holding B V | Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques |
| CN120983617A (zh) | 2018-11-06 | 2025-11-21 | 健玛保 | 抗体配制剂 |
| PH12021551547A1 (en) | 2018-12-31 | 2022-08-15 | Merus Nv | Mixed binding domains |
| MA54643A (fr) | 2018-12-31 | 2021-11-10 | Merus Nv | Multimères multivalents tronqués |
| AU2020226445B2 (en) | 2019-02-18 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with humanized immunoglobulin locus |
| CN119661722A (zh) | 2019-02-21 | 2025-03-21 | 马伦戈治疗公司 | 结合t细胞相关癌细胞的多功能分子及其用途 |
| WO2020172598A1 (en) | 2019-02-21 | 2020-08-27 | Elstar Therapeutics, Inc. | Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders |
| GB2598218B (en) | 2019-02-21 | 2024-05-08 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| CA3131016A1 (en) | 2019-02-21 | 2020-08-27 | Andreas Loew | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3927747A1 (en) | 2019-02-21 | 2021-12-29 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| TW202039578A (zh) | 2019-03-29 | 2020-11-01 | 荷蘭商美勒斯公司 | Cd3結合分子 |
| TWI862565B (zh) | 2019-04-04 | 2024-11-21 | 日商小野藥品工業股份有限公司 | 雙特異性抗體 |
| TW202108613A (zh) | 2019-05-09 | 2021-03-01 | 荷蘭商美勒斯公司 | 用於多聚化蛋白質及其分離的變異區域 |
| US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| TWI889320B (zh) | 2019-07-05 | 2025-07-01 | 日商小野藥品工業股份有限公司 | 以pd-1/cd3雙特異性蛋白質所進行之血液性癌症治療 |
| BR112022001473A2 (pt) | 2019-07-30 | 2022-03-22 | Ono Pharmaceutical Co | Anticorpo biespecífico |
| EP3772518A1 (en) | 2019-08-07 | 2021-02-10 | Merus N.V. | Modified human variable domains |
| GB201912008D0 (en) | 2019-08-21 | 2019-10-02 | Cambridge Entpr Ltd | Antibody |
| US20220411529A1 (en) | 2019-11-06 | 2022-12-29 | Genmab B.V. | Antibody variant combinations and uses thereof |
| TWI774137B (zh) | 2019-11-26 | 2022-08-11 | 大陸商上海岸邁生物科技有限公司 | 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白 |
| PH12022551527A1 (en) | 2019-12-24 | 2024-01-29 | Merus Nv | Tgf-beta-rii binding proteins |
| GB2609554B (en) | 2020-01-03 | 2025-08-20 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| WO2021138407A2 (en) | 2020-01-03 | 2021-07-08 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to cd33 and uses thereof |
| PE20230113A1 (es) | 2020-01-16 | 2023-01-27 | Genmab As | Formulaciones de anticuerpos anti-cd38 y usos de las mismas |
| CN114945596A (zh) | 2020-01-29 | 2022-08-26 | 美勒斯公司 | 用于调节免疫细胞衔接效应的手段和方法 |
| WO2021155916A1 (en) | 2020-02-04 | 2021-08-12 | BioNTech SE | Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137 |
| AU2021236906A1 (en) | 2020-03-18 | 2022-08-18 | Genmab A/S | Antibodies binding to B7H4 |
| WO2021211510A2 (en) * | 2020-04-13 | 2021-10-21 | Affyimmune Therapeutics, Inc. | Epcam antibody and car-t cells |
| KR20230028242A (ko) | 2020-04-24 | 2023-02-28 | 마렝고 테라퓨틱스, 인크. | T 세포 관련 암 세포에 결합하는 다중기능성 분자 및 그것의 용도 |
| US20230227570A1 (en) | 2020-05-08 | 2023-07-20 | Genmab A/S | Bispecific antibodies against cd3 and cd20 |
| EP4153315A1 (en) | 2020-05-21 | 2023-03-29 | Merus N.V. | Methods and means for the production of ig-like molecules |
| AU2021283564B2 (en) | 2020-06-02 | 2025-05-29 | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. | Genetically modified non-human animals with common light chain immunoglobulin locus |
| EP4185388A1 (en) | 2020-07-23 | 2023-05-31 | Genmab B.V. | A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| CA3170741A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| AU2021322046A1 (en) | 2020-08-06 | 2023-02-02 | BioNTech SE | Binding agents for coronavirus S protein |
| AU2021331075A1 (en) | 2020-08-26 | 2023-04-06 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| CA3190766A1 (en) | 2020-08-26 | 2022-03-03 | Marengo Therapeutics, Inc. | Antibody molecules that bind to nkp30 and uses thereof |
| GB2616354A (en) | 2020-08-26 | 2023-09-06 | Marengo Therapeutics Inc | Methods of detecting TRBC1 or TRBC2 |
| JP2023541860A (ja) | 2020-09-10 | 2023-10-04 | ジェンマブ エー／エス | びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体 |
| CA3190349A1 (en) | 2020-09-10 | 2022-03-17 | Brian Elliott | Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia |
| CN116438198A (zh) | 2020-10-02 | 2023-07-14 | 健玛保 | 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体 |
| CN116710486A (zh) | 2020-12-16 | 2023-09-05 | 美勒斯公司 | 用于治疗癌症的多特异性抗体 |
| JP2024512386A (ja) | 2021-03-12 | 2024-03-19 | ジェンマブ エー／エス | 非活性化抗体バリアント |
| KR20240004462A (ko) | 2021-04-08 | 2024-01-11 | 마렝고 테라퓨틱스, 인크. | Tcr에 결합하는 다기능성 분자 및 이의 용도 |
| JP2024519212A (ja) | 2021-05-07 | 2024-05-09 | ジェンマブ エー／エス | Ｂ７ｈ４およびｃｄ３に結合する二重特異性抗体を含む薬学的組成物 |
| US20240262924A1 (en) | 2021-06-21 | 2024-08-08 | Genmab A/S | Combination dosage regime of cd137 and pd-l1 binding agents |
| KR20240051280A (ko) | 2021-09-06 | 2024-04-19 | 젠맵 에이/에스 | Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도 |
| JP7503215B2 (ja) | 2021-10-08 | 2024-06-19 | ジェンマブ エー／エス | Ｃｄ３０及びｃｄ３に結合する抗体 |
| CN118632872A (zh) | 2022-01-25 | 2024-09-10 | 美勒斯公司 | 用于治疗癌症的组合疗法 |
| WO2023174521A1 (en) | 2022-03-15 | 2023-09-21 | Genmab A/S | Binding agents binding to epcam and cd137 |
| WO2023218051A1 (en) | 2022-05-12 | 2023-11-16 | Genmab A/S | Binding agents capable of binding to cd27 in combination therapy |
| IL316628A (en) | 2022-05-12 | 2024-12-01 | Genmab As | Binding agents capable of binding to CD27 in combination therapy |
| KR20250049569A (ko) | 2022-07-15 | 2025-04-11 | 페온 테라퓨틱스 리미티드 | 항체-약물 접합체 |
| WO2024094660A1 (en) | 2022-10-31 | 2024-05-10 | Genmab A/S | Cd38 antibodies and uses thereof |
| EP4644548A1 (en) | 2022-12-27 | 2025-11-05 | Chugai Seiyaku Kabushiki Kaisha | Polypeptide with controlled association |
| CN116333103B (zh) * | 2023-02-09 | 2025-10-10 | 广州国家实验室 | 抗沙贝病毒属病毒的中和抗体及其制备方法和应用 |
| TW202506178A (zh) | 2023-04-05 | 2025-02-16 | 丹麥商珍美寶股份有限公司 | 包含與ｃｄ３０和ｃｄ３結合之抗體之醫藥組成物 |
| AR132668A1 (es) | 2023-05-12 | 2025-07-16 | Genmab As | Anticuerpos capaces de unirse a ox40, variantes de los mismos y usos de los mismos |
| TW202509077A (zh) | 2023-06-30 | 2025-03-01 | 丹麥商珍美寶股份有限公司 | 與纖維母細胞活化蛋白α及死亡受體４結合之抗體 |
| WO2025056180A1 (en) | 2023-09-15 | 2025-03-20 | BioNTech SE | Methods of treatment using agents binding to epcam and cd137 in combination with pd-1 axis binding antagonists |
| WO2025114541A1 (en) | 2023-11-30 | 2025-06-05 | Genmab A/S | Antibodies capable of binding to ox40 in combination therapy |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (209)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5180502A (ja) | 1974-12-28 | 1976-07-14 | Seirei Ind | Tsumejikufurikaeshikiseigyakutenkonsochi |
| US4634665A (en) * | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) * | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4599311A (en) * | 1982-08-13 | 1986-07-08 | Kawasaki Glenn H | Glycolytic promotersfor regulated protein expression: protease inhibitor |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU600885B2 (en) | 1984-05-25 | 1990-08-30 | Zymogenetics Inc. | Stable DNA constructs |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US4868103A (en) * | 1986-02-19 | 1989-09-19 | Enzo Biochem, Inc. | Analyte detection by means of energy transfer |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US4801687A (en) | 1986-10-27 | 1989-01-31 | Bioprobe International, Inc. | Monoclonal antibody purification process using protein A |
| US4937190A (en) * | 1987-10-15 | 1990-06-26 | Wisconsin Alumni Research Foundation | Translation enhancer |
| US5202238A (en) * | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| FI884924L (fi) | 1987-10-28 | 1989-04-29 | Oncogen | Humanimmuglobulin som producerats med hybrid-dna-teknik. |
| EP0317156B2 (en) * | 1987-11-09 | 1997-11-12 | Becton, Dickinson and Company | Method for analysis of hematopoietic cells in a sample |
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8909218D0 (en) | 1989-04-22 | 1989-06-07 | Medical Res Council | Improvements in or relating to enhancers |
| ES2062364T3 (es) | 1989-06-08 | 1994-12-16 | Wistar Inst | Un metodo de preparacion de una composicion para el tratamiento despues de la exposicion de infeccion de rabia. |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| US5030002A (en) | 1989-08-11 | 1991-07-09 | Becton, Dickinson And Company | Method and apparatus for sorting particles with a moving catcher tube |
| US5959177A (en) † | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5151504A (en) | 1989-11-17 | 1992-09-29 | E. R. Squibb & Sons, Inc. | Method for purification of monoclonal antibodies |
| AU656720B2 (en) † | 1989-12-01 | 1995-02-16 | Gene Pharming Europe Bv | Production of recombinant polypeptides by bovine species and transgenic methods |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| DE4006630A1 (de) | 1990-03-03 | 1991-09-12 | Behringwerke Ag | Humane monoklonale antikoerper gegen tollwutviren, ihre herstellung und verwendung |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| JPH0568599A (ja) | 1990-07-31 | 1993-03-23 | Wistar Inst | 遺伝子工学的に作られた抗体 |
| IE76732B1 (en) * | 1990-08-07 | 1997-11-05 | Becton Dickinson Co | One step test for absolute counts |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) † | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| JP3438889B2 (ja) | 1991-03-29 | 2003-08-18 | ジェネンテク，インコーポレイテッド | 所望のタンパク質を高レベルに発現させる組換え宿主細胞の選別法 |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE243747T1 (de) | 1991-07-15 | 2003-07-15 | Wellcome Found | Herstellung von antikörpern |
| WO1993004169A1 (en) | 1991-08-20 | 1993-03-04 | Genpharm International, Inc. | Gene targeting in animal cells using isogenic dna constructs |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| CA2087413A1 (en) * | 1992-01-17 | 1993-07-18 | Joseph R. Lakowicz | Fluorescent energy transfer immunoassay |
| US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US7067284B1 (en) * | 1992-01-27 | 2006-06-27 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| SE9201984D0 (sv) * | 1992-06-29 | 1992-06-29 | Pharmacia Biosensor Ab | Improvement in optical assays |
| EP0651805B1 (en) * | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method of intracellular binding of target molecules |
| WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
| DE4228162C1 (de) | 1992-08-25 | 1994-01-13 | Rajewsky Klaus Dr | Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern |
| EP1238986B1 (en) | 1992-10-28 | 2008-06-25 | Genentech, Inc. | Use of Vascular endothelial cell growth factor antagonists |
| DE669986T1 (de) | 1992-11-13 | 1996-10-10 | Idec Pharma Corp | Völlig unfunktionelle konsensus-kozak-sequenzen zur säugetier-exprimierung. |
| WO1994023046A1 (en) | 1993-04-07 | 1994-10-13 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Dna sequence which acts as a chromatin insulator element to protect expressed genes from cis-acting regulatory sequences in mammalian cells |
| DE69427974T2 (de) | 1993-04-29 | 2001-12-06 | Unilever N.V., Rotterdam | Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae |
| JPH09501055A (ja) | 1993-07-30 | 1997-02-04 | ユニバーシティ オブ メディシン アンド デンティストリー オブ ニュージャージー | 初代リンパ球への効率的遺伝子転移 |
| US5693506A (en) † | 1993-11-16 | 1997-12-02 | The Regents Of The University Of California | Process for protein production in plants |
| US5827690A (en) † | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| EP0739412B1 (en) † | 1993-12-23 | 2002-02-27 | Infigen, Inc. | ungulate EMBRYONIC STEM CELLS AS NUCLEAR DONORS AND NUCLEAR TRANSFER TECHNIQUES TO PRODUCE CHIMERIC AND TRANSGENIC ANIMALS |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| FR2717187B1 (fr) | 1994-03-10 | 1996-05-31 | Transgene Sa | Usage combiné de deux cassettes d'expression pour la production d'une protéine d'intérêt. |
| US6080560A (en) † | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| JPH08116978A (ja) | 1994-10-18 | 1996-05-14 | Nisshinbo Ind Inc | 抗体Ｆａｂライブラリーの作製法 |
| EP0807173B1 (en) * | 1994-12-30 | 2007-08-08 | Planet Biotechnology, Inc. | Methods for producing immunoglobulins containing protection proteins in plants and their use |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6130364A (en) | 1995-03-29 | 2000-10-10 | Abgenix, Inc. | Production of antibodies using Cre-mediated site-specific recombination |
| US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US5885827A (en) | 1996-01-23 | 1999-03-23 | The Regents Of The Universtiy Of California | Eukaryotic high rate mutagenesis system |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6825396B2 (en) | 1996-06-12 | 2004-11-30 | Board Of Trustees Operating Michigan State University | Methods for tissue specific synthesis of protein in eggs of transgenic hens |
| CA2267139A1 (en) | 1996-10-08 | 1998-04-16 | Ton Logtenberg | Methods and means for selecting peptides and proteins having specific affinity for a target |
| GB9621113D0 (en) | 1996-10-10 | 1996-11-27 | Univ Southampton | Transgenic fish |
| WO1998024923A1 (en) | 1996-12-02 | 1998-06-11 | Wake Forest University | Inactivation of hiv co-receptors as therapy for hiv infection |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| PT971946E (pt) * | 1997-01-21 | 2006-11-30 | Gen Hospital Corp | Selecção de proteínas utilizando fusões arn-proteína |
| NZ337495A (en) † | 1997-03-06 | 2001-06-29 | Infigen Inc | Bovine primordial germ cells and their use in cloning |
| CA2283740C (en) | 1997-03-14 | 2006-06-27 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US5830698A (en) * | 1997-03-14 | 1998-11-03 | Idec Pharmaceuticals Corporation | Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same |
| US6080912A (en) | 1997-03-20 | 2000-06-27 | Wisconsin Alumni Research Foundation | Methods for creating transgenic animals |
| CN1203922A (zh) * | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
| ES2236634T3 (es) | 1997-04-07 | 2005-07-16 | Genentech, Inc. | Anticuerpos anti-vegf. |
| US20020062010A1 (en) * | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| US20030207346A1 (en) * | 1997-05-02 | 2003-11-06 | William R. Arathoon | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0979281B1 (en) * | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| JP2001517453A (ja) | 1997-09-23 | 2001-10-09 | オックスフォード バイオメディカ（ユーケイ）リミテッド | 方 法 |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| BR9813276A (pt) | 1997-10-27 | 2000-08-22 | Unilever Nv | Proteìna multivalente de ligação de antìgeno, sequências de nucleotìdeos, vetor de expressão, célula hospedeira, processo para preparação de proteìna multivalente de ligação de antìgeno, e, uso da mesma |
| DE69823652D1 (de) | 1997-11-26 | 2004-06-09 | Mitsubishi Precision Co Ltd | Informationsleitungssystem |
| US6074385A (en) | 1998-02-03 | 2000-06-13 | Kiefer Corp. | Hair follicle devitalization by induced heating of magnetically susceptible particles |
| CA2325721A1 (en) | 1998-03-30 | 1999-10-07 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| CN1241574A (zh) * | 1998-07-02 | 2000-01-19 | 中国人民解放军第四军医大学 | 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体 |
| GB9823930D0 (en) † | 1998-11-03 | 1998-12-30 | Babraham Inst | Murine expression of human ig\ locus |
| CA2361553A1 (en) | 1999-01-29 | 2000-08-03 | Zhenping Zhu | Antibodies specific to kdr and uses thereof |
| ATE289354T1 (de) | 1999-04-15 | 2005-03-15 | Crucell Holland Bv | Verwendung von adenovirus e1 protein sequenzen kodierenden, zur herstellung von rekombinanten proteinen in menschlichen zellen. |
| ATE421976T1 (de) | 1999-05-18 | 2009-02-15 | Dyax Corp | Fab fragmentbibliotheken und verfahren für deren verwendung |
| US6472147B1 (en) | 1999-05-25 | 2002-10-29 | The Scripps Research Institute | Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| GEP20104998B (en) | 1999-06-25 | 2010-06-10 | Genentech Inc | Humanized antibody which binds erbb2 and blocks activation by ligand receptor of erbb2 (variants) and use of the composition comprising these antibodies methods for treating cancer |
| AU7491800A (en) | 1999-09-15 | 2001-04-17 | Therapeutic Human Polyclonals, Inc. | Immunotherapy with substantially human polyclonal antibody preparations purifiedfrom genetically engineered birds |
| US6180357B1 (en) | 1999-10-08 | 2001-01-30 | Arius Research, Inc. | Individualized patient-specific anti-cancer antibodies |
| WO2001027279A1 (en) * | 1999-10-12 | 2001-04-19 | Cambridge Antibody Technology | Human anti-adipocyte monoclonal antibodies and their use |
| US6316253B1 (en) | 1999-11-01 | 2001-11-13 | Chiron Corporation | Expression vectors, transfection systems, and method of use thereof |
| GB9928787D0 (en) * | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
| EP1242823B1 (en) | 1999-12-27 | 2007-07-04 | Crucell Holland B.V. | Selecting library members capable of binding to epitopes |
| CA2401965A1 (en) † | 2000-02-29 | 2001-09-07 | Auburn University | Production of antibodies in transgenic plastids |
| US20040180046A1 (en) | 2000-04-26 | 2004-09-16 | Jeff Himawan | Bispecific molecules and uses thereof |
| IL152825A (en) | 2000-05-16 | 2009-07-20 | Univ Jefferson | Rabies virus-specific neutralizing human monoclonal antibodies and nucleic acids and related methods |
| EP2386575A3 (en) | 2000-06-29 | 2011-11-30 | Abbott Laboratories | Dual specificity antibodies and methods of making and using |
| CN1334343A (zh) * | 2000-07-14 | 2002-02-06 | 中国医学科学院肿瘤医院肿瘤研究所 | 抑制肿瘤生长的新抗体、其衍生物及其应用 |
| EP1184458A1 (en) † | 2000-08-28 | 2002-03-06 | U-BISys B.V. | Differentially expressed CD46 epitopes, proteinaceous molecules capable of binding thereto, and uses thereof |
| EP1188771A1 (en) | 2000-09-15 | 2002-03-20 | U-BISys B.V. | Libraries of human heavy chain variable fragments in a functional format |
| US7737258B2 (en) | 2000-10-18 | 2010-06-15 | Sloan-Kettering Institute For Cancer Research | Uses of monoclonal antibody 8H9 |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| DK1354034T3 (da) | 2000-11-30 | 2008-03-25 | Medarex Inc | Transgene transchromosomale gnavere til fremstilling af humane antistoffer |
| FR2817875B1 (fr) | 2000-12-07 | 2005-03-18 | Technopharm | Procede de preparation d'un anticorps monoclonal humain, de fragments de celui-ci ou d'anticorps comprenant de tels fragments, les anticorps ainsi obtenus et leur utilisation |
| WO2002059297A2 (en) | 2001-01-25 | 2002-08-01 | Evolva Biotech A/S | A library of a collection of cells |
| ATE437233T1 (de) | 2001-01-26 | 2009-08-15 | Selexis Sa | Matrix-anheftungsregionen und verfahren zu deren verwendung |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US7795494B2 (en) | 2001-03-22 | 2010-09-14 | Abbott Laboratories | Transgenic mice expressing antibodies specific for genes of interest and uses thereof |
| GB0110029D0 (en) | 2001-04-24 | 2001-06-13 | Grosveld Frank | Transgenic animal |
| US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| CZ200438A3 (cs) * | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
| US7329530B2 (en) | 2001-06-15 | 2008-02-12 | Crucell Holland B.V. | Chimaeric phages |
| DE60237282D1 (de) | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| CA2812799C (en) | 2001-07-04 | 2016-01-26 | Chromagenics B.V. | Dna sequences comprising gene transcription regulatory qualities and methods for detecting and using such dna sequences |
| ATE557040T1 (de) | 2001-08-21 | 2012-05-15 | Univ Jefferson | Rekombinante antikörper sowie zusammensetzungen und verfahren zu deren herstellung und verwendung |
| JP4461210B2 (ja) | 2001-08-27 | 2010-05-12 | ジェネンテック， インコーポレイテッド | 抗体発現系とその構築法 |
| EP2022799A2 (en) | 2001-11-16 | 2009-02-11 | Biogen Idec Inc. | Polycistronic expression of antibodies |
| WO2003046012A1 (en) | 2001-11-30 | 2003-06-05 | Crucell Holland B.V. | Antigen presenting cell targeting conjugate, an antigen presenting cell contacted with such conjugate, their use for vaccination or as medicament, and methods for their production or generation |
| DK1456651T3 (da) | 2001-11-30 | 2008-09-01 | Ca Nat Research Council | Selvsamlende molekyler |
| US20030215914A1 (en) | 2001-12-10 | 2003-11-20 | Erwin Houtzager | Structure for presenting desired peptide sequences |
| US20050037427A1 (en) | 2001-12-10 | 2005-02-17 | Erwin Houtzager | Structure for presenting desired peptide sequences |
| US7244592B2 (en) * | 2002-03-07 | 2007-07-17 | Dyax Corp. | Ligand screening and discovery |
| GB2387030A (en) | 2002-03-26 | 2003-10-01 | Thales Plc | Compensation of mutual coupling in array antenna systems |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| ITGE20020049A1 (it) | 2002-06-05 | 2003-12-05 | Ali Spa | Dispositivo a pistone per la erogazione di quantitativi dosati di sostanze pastose, quali i gelati, applicabile alle macchine per la loro fa |
| EP1513936A2 (en) | 2002-06-14 | 2005-03-16 | Chromagenics B.V. | Use of repression blocking sequences in methods for enhancing gene expression |
| WO2003106684A2 (en) | 2002-06-14 | 2003-12-24 | Chromagenics B.V. | A method for simultaneous production of multiple proteins; vectors and cells for use therein |
| AU2002368062A1 (en) | 2002-06-26 | 2004-01-19 | Imclone Systems Incorporated | Bispecific antibodies that bind to vegf receptors |
| US20080241166A1 (en) | 2002-06-28 | 2008-10-02 | Domantis Limited | Ligands that bind a receptor |
| CN1328446C (zh) | 2002-07-10 | 2007-07-25 | 阿戈什蒂诺·迪特拉帕尼 | 建筑元件 |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| SI1523496T1 (sl) * | 2002-07-18 | 2011-11-30 | Merus B V | Rekombinantno proizvajanje zmesi protiteles |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| EP1439234A1 (en) | 2003-01-08 | 2004-07-21 | ARTEMIS Pharmaceuticals GmbH | Targeted transgenesis using the rosa26 locus |
| EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| CA2529001A1 (en) | 2003-06-10 | 2004-12-16 | Catchmabs B.V. | Binding peptides: methods for their generation and use |
| CA2531684C (en) | 2003-07-22 | 2014-03-11 | Crucell Holland B.V. | Binding molecules against sars-coronavirus and uses thereof |
| JP4712724B2 (ja) | 2003-12-23 | 2011-06-29 | クルセル ホランド ベー ヴェー | ＣＤ１ａに対するヒト結合分子 |
| EP1737971B1 (en) | 2004-01-20 | 2017-08-16 | Merus N.V. | Mixtures of binding proteins |
| HRP20110320T1 (hr) | 2004-05-27 | 2011-05-31 | Crucell Holland B.V. | Molekule za vezanje koje mogu neutralizirati virus bjesnoće i njihova uporaba |
| ES2526343T3 (es) | 2004-06-03 | 2015-01-09 | Novimmune Sa | Anticuerpos anti-CD3 y métodos de uso de los mismos |
| CA2577082A1 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| JP4487068B2 (ja) | 2004-10-12 | 2010-06-23 | 国立大学法人 岡山大学 | 細胞の遺伝子変異機能の制御による変異タンパク質の作製方法 |
| JP4852046B2 (ja) | 2004-10-12 | 2012-01-11 | クルセル ホランド ベー ヴェー | 癌の治療及び検出に用いる結合分子 |
| CA2582057C (en) | 2004-11-11 | 2015-08-11 | Crucell Holland B.V. | Compositions against sars-coronavirus and uses thereof |
| JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
| WO2006117699A2 (en) | 2005-04-29 | 2006-11-09 | Innate Pharma | Transgenic animals and methods of making recombinant antibodies |
| WO2006120230A2 (en) | 2005-05-12 | 2006-11-16 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| WO2006136601A1 (en) | 2005-06-23 | 2006-12-28 | Crucell Holland B.V. | Optimization of west nile virus antibodies |
| US8642513B2 (en) | 2005-09-15 | 2014-02-04 | Crucell Holland B.V. | Method for preparing immunoglobulin libraries |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| EP2505058A1 (en) | 2006-03-31 | 2012-10-03 | Medarex, Inc. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| EA016717B1 (ru) | 2006-06-06 | 2012-07-30 | Круселл Холланд Б.В. | Моноклональное антитело человека, обладающее опсонизирующей фагоцитарной киллерной активностью в отношении enterococcus и staphylococcus aureus, и его применение |
| EA018030B1 (ru) | 2006-06-06 | 2013-05-30 | Круселл Холланд Б.В. | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| MY170607A (en) | 2006-09-07 | 2019-08-20 | Crucell Holland Bv | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| WO2008054606A2 (en) | 2006-10-02 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
| US8290739B2 (en) | 2006-10-20 | 2012-10-16 | Amfit, Inc. | Method for determining relative mobility of regions of an object |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| AU2008234248C1 (en) | 2007-03-29 | 2015-01-22 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| ITMI20071522A1 (it) | 2007-07-27 | 2009-01-28 | Areta Internat S R L | Vaccino idiotipico |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| US8536310B2 (en) | 2007-10-17 | 2013-09-17 | Arca Biopharma, Inc. | Antibodies to CLL-1 |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| PT2235064E (pt) | 2008-01-07 | 2016-03-01 | Amgen Inc | Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática |
| EP2245571B1 (en) | 2008-02-05 | 2019-04-10 | Zymeworks Inc. | Methods for determining correlated residues in a protein or other biopolymer using molecular dynamics |
| RU2559524C2 (ru) | 2008-06-27 | 2015-08-10 | Мерюс Б.В. | Продуцирующие антитела млекопитающие, не являющиеся человеком |
| CN102365296A (zh) | 2009-01-26 | 2012-02-29 | 根马布股份公司 | 用于生成抗体混合物的方法 |
| CN102459346B (zh) | 2009-04-27 | 2016-10-26 | 昂考梅德药品有限公司 | 制造异源多聚体分子的方法 |
| WO2010130636A1 (en) | 2009-05-11 | 2010-11-18 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof |
| MX368932B (es) | 2009-06-26 | 2019-10-22 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| SMT201900372T1 (it) | 2010-02-08 | 2019-09-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| EP2569337A1 (en) | 2010-05-14 | 2013-03-20 | Rinat Neuroscience Corp. | Heterodimeric proteins and methods for producing and purifying them |
| US20130177555A1 (en) | 2010-08-13 | 2013-07-11 | Medimmune Limited | Monomeric Polypeptides Comprising Variant FC Regions And Methods Of Use |
| EP2606064B1 (en) | 2010-08-16 | 2015-02-25 | NovImmune S.A. | Methods for the generation of multispecific and multivalent antibodies |
| RU2604490C2 (ru) | 2010-11-05 | 2016-12-10 | Займворкс Инк. | ДИЗАЙН УСТОЙЧИВОГО ГЕТЕРОДИМЕРНОГО АНТИТЕЛА С МУТАЦИЯМИ В Fc ДОМЕНЕ |
| DK2813573T1 (da) | 2011-02-25 | 2015-01-12 | Regeneron Pharma | ADAM6 mus |
| SG10201602371VA (en) | 2011-03-25 | 2016-04-28 | Glenmark Pharmaceuticals Sa | Hetero-dimeric immunoglobulins |
| JP2013004215A (ja) | 2011-06-14 | 2013-01-07 | Hitachi Ltd | リチウムイオン二次電池 |
| JP2016184957A (ja) | 2012-02-09 | 2016-10-20 | シャープ株式会社 | 情報処理装置及び情報処理方法 |
| ES2743399T3 (es) | 2012-04-20 | 2020-02-19 | Merus Nv | Métodos y medios para la producción de moléculas heterodiméricas similares a Ig |
| US10358492B2 (en) | 2012-09-27 | 2019-07-23 | Merus N.V. | Bispecific IgG antibodies as T cell engagers |
-
2003
- 2003-07-15 SI SI200332045T patent/SI1523496T1/sl unknown
- 2003-07-15 PT PT101860633T patent/PT2314629E/pt unknown
- 2003-07-15 AT AT03764997T patent/ATE514717T1/de active
- 2003-07-15 NZ NZ537277A patent/NZ537277A/en not_active IP Right Cessation
- 2003-07-15 DK DK03764997.7T patent/DK1523496T3/da active
- 2003-07-15 ES ES03764997T patent/ES2368733T3/es not_active Expired - Lifetime
- 2003-07-15 JP JP2004522465A patent/JP4836451B2/ja not_active Expired - Lifetime
- 2003-07-15 AU AU2003250074A patent/AU2003250074B2/en not_active Expired
- 2003-07-15 EP EP10186063.3A patent/EP2314629B2/en not_active Expired - Lifetime
- 2003-07-15 PT PT03764997T patent/PT1523496E/pt unknown
- 2003-07-15 CN CNB038170779A patent/CN100480260C/zh not_active Expired - Lifetime
- 2003-07-15 ES ES10186063T patent/ES2442615T5/es not_active Expired - Lifetime
- 2003-07-15 CA CA2965865A patent/CA2965865C/en not_active Expired - Lifetime
- 2003-07-15 CN CN200910132819.2A patent/CN101537180B/zh not_active Expired - Lifetime
- 2003-07-15 CA CA2492377A patent/CA2492377C/en not_active Expired - Lifetime
- 2003-07-15 CA CA2872136A patent/CA2872136C/en not_active Expired - Lifetime
- 2003-07-15 CN CN201610051739.4A patent/CN105884893A/zh active Pending
- 2003-07-15 EP EP03764997A patent/EP1523496B1/en not_active Expired - Lifetime
- 2003-07-15 WO PCT/EP2003/007690 patent/WO2004009618A2/en not_active Ceased
- 2003-07-15 DK DK10186063.3T patent/DK2314629T4/da active
-
2005
- 2005-01-18 US US11/039,767 patent/US7262028B2/en not_active Expired - Lifetime
-
2006
- 2006-11-06 US US11/593,280 patent/US7932360B2/en not_active Expired - Lifetime
- 2006-11-06 US US11/593,279 patent/US7429486B2/en not_active Expired - Lifetime
-
2008
- 2008-07-29 US US12/221,021 patent/US7927834B2/en not_active Expired - Lifetime
-
2010
- 2010-12-02 AU AU2010249150A patent/AU2010249150B9/en not_active Expired
-
2011
- 2011-03-04 US US12/932,719 patent/US9303081B2/en not_active Expired - Lifetime
- 2011-05-30 JP JP2011121054A patent/JP6049239B2/ja not_active Expired - Lifetime
- 2011-09-23 CY CY20111100924T patent/CY1111886T1/el unknown
-
2013
- 2013-03-12 US US13/795,637 patent/US20130243773A1/en not_active Abandoned
-
2014
- 2014-07-03 JP JP2014137927A patent/JP6166693B2/ja not_active Expired - Fee Related
-
2016
- 2016-04-04 US US15/090,505 patent/US10934571B2/en not_active Expired - Fee Related
- 2016-09-21 JP JP2016184803A patent/JP2016220696A/ja active Pending
-
2017
- 2017-12-14 US US15/842,303 patent/US20180094289A1/en not_active Abandoned
- 2017-12-27 US US15/855,258 patent/US20180112247A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2965865C (en) | Recombinant production of mixtures of antibodies | |
| AU2017279594B2 (en) | Recombinant production of mixtures of antibodies | |
| USRE47770E1 (en) | Recombinant production of mixtures of antibodies | |
| HK1070902B (en) | Recombinant production of mixtures of antibodies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| ASS | Change of ownership |
Owner name: MERUS B.V., NL Free format text: OLD OWNER(S): CRUCELL HOLLAND B.V. |
|
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 15 JUL 2016 BY DENNEMEYER + CO Effective date: 20130725 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2017 BY DENNEMEYER + CO Effective date: 20160622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2018 BY DENNEMEYER + CO Effective date: 20170622 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2019 BY DENNEMEYER + CO. Effective date: 20180621 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2020 BY DENNEMEYER CO. Effective date: 20190620 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2021 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20200706 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2022 BY DENNEMEYER+CO. Effective date: 20210705 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 15 JUL 2023 BY DENNEMEYER + CO. S.A.R.L. Effective date: 20220704 |
|
| EXPY | Patent expired |